Literature DB >> 15215727

Palliative care in the management of chronic obstructive pulmonary disease.

Laura Blackler1, Caroline Mooney, Christine Jones.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a slow, debilitating, progressive disease and, as symptoms worsen, quality of life is affected and issues surrounding end of life arise. There are known difficulties about the healthcare professional's ability to manage this area and this is reflected in the literature. It is recognized that palliative care services for people with non-malignant diseases are not developed but this needs to be addressed. Within a London teaching hospital the COPD team has been working towards improving the standard of service offered to patients with advanced COPD using various strategies. The team's approach to this area of care focuses on quality of life by recognizing when an individual may need further support, and patients have reported that they feel their needs are being addressed. This article aims to review current evidence on the management of palliative care for patients with COPD and identify what steps have been taken by a London teaching hospital to address this issue.

Entities:  

Mesh:

Year:  2004        PMID: 15215727     DOI: 10.12968/bjon.2004.13.9.12960

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  4 in total

1.  [Symptom control and ethics in final stages of COPD].

Authors:  Bernadette Hörfarter; Dietmar Weixler
Journal:  Wien Med Wochenschr       Date:  2006-05

Review 2.  Palliative care in non-malignant diseases.

Authors:  D C Traue; J R Ross
Journal:  J R Soc Med       Date:  2005-11       Impact factor: 18.000

Review 3.  End of life care in chronic obstructive pulmonary disease: in search of a good death.

Authors:  Anna Spathis; Sara Booth
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

4.  Palliative care in COPD--web survey in Sweden highlights the current situation for a vulnerable group of patients.

Authors:  Susann Strang; Ann Ekberg-Jansson; Peter Strang; Lars-Olof Larsson
Journal:  Ups J Med Sci       Date:  2013-05-28       Impact factor: 2.384

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.